Open Label, Multicenter Phase I Study of IPH4102, a Humanized Anti-KIR3DL2 Monoclonal Antibody, in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)

Trial Profile

Open Label, Multicenter Phase I Study of IPH4102, a Humanized Anti-KIR3DL2 Monoclonal Antibody, in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs IPH 4102 (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Innate Pharma
  • Most Recent Events

    • 16 Oct 2017 According to an Innate Pharma media release, final results of the dose-escalation part of this trial were presented in an oral presentation at the EORTC CLTF meeting 2017.
    • 16 Oct 2017 Results presented in an Innate Pharma media release.
    • 16 Oct 2017 According to an Innate Pharma media release, Expansion cohorts started, including 2 cohorts of 15 patients each in two CTCL subtypes: Sezary syndrome and transformed mycosis fungoides.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top